ZURICH (Reuters) – Roche’s experimental drug gantenerumab failed to slow cognitive decline in people with a rare inherited form of Alzheimer’s disease, the latest setback for companies hunting for a cure for the devastating brain-wasting disease. The study foc... More »
(Reuters) – Alzheimer’s researchers have proposed a radical change in the way the disease is defined, focusing on biological changes in the body rather than clinical symptoms such as memory loss and cognitive decline. The new research framework, released on Tu... More »
FILE PHOTO – A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason Reed/File Photo (Reuters) – U.S. regulators have proposed lowering the bar for clinical trial success for experimental ... More »
TOKYO/MELBOURNE (Reuters) – Researchers in Japan and Australia say they have made important progress in developing a blood test that could in future help doctors detect who might go on to get Alzheimer’s disease. In a study published in the journal Nature, the... More »
Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer’s drug after it was determined that it had no chance of working, marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind... More »
Two remaining late-stage clinical trials testing an experimental Alzheimer’s drug from Denmark’s Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of developing such treatments. More »
LONDON Alzheimer’s disease is moving out of the shadows as new plays tackle head-on the emotional pain of a condition that robs its victims of words, memories and coherent thought. For a generation of young playwrights, dementia is proving to be a touchstone i... More »
